SCHEMBL2207717

SCHEMBL2207717

COc1cccc2sc(C(O)[C@H]3CC[C@H](NC(=O)OC(C)(C)C)CC3)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.42
KDM1A O60341 1/20 0.41
MAOB P27338 1/20 0.41
CACNB4 O00305 1/20 0.41
CACNA1A O00555 1/20 0.41
CACNA1G O43497 1/20 0.41
CACNG3 O60359 1/20 0.41
CACNA1F O60840 1/20 0.41
CACNA1H O95180 1/20 0.41
CACNB3 P54284 1/20 0.41
CACNA2D1 P54289 1/20 0.41
CACNG7 P62955 1/20 0.41
CACNA1B Q00975 1/20 0.41
CACNA1D Q01668 1/20 0.41
CACNB1 Q02641 1/20 0.41
CACNG1 Q06432 1/20 0.41
CACNB2 Q08289 1/20 0.41
CACNA1S Q13698 1/20 0.41
CACNA1C Q13936 1/20 0.41
CACNA1E Q15878 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2207723 1.00 DYRK1A (0.42) DYRK1AKDM1AMAOBCACNB4CACNA1A
SCHEMBL2207836 0.82 CACNB4 (0.48) DYRK1AKDM1AMAOBCACNB4CACNA1A
SCHEMBL2207832 0.82 CACNB4 (0.48) DYRK1AKDM1AMAOBCACNB4CACNA1A
SCHEMBL2204384 0.78 TDP1 (0.49) DYRK1ACHRM4ALDH1A1DUSP3MAPT
SCHEMBL3053547 0.72 DYRK1A (0.70) DYRK1ACHRM4ALDH1A1DUSP3MAPT
SCHEMBL2203596 0.69 KDM1A (0.40) KDM1AMAOBCACNB4CACNA1ACACNA1G
SCHEMBL2203600 0.69 KDM1A (0.40) KDM1AMAOBCACNB4CACNA1ACACNA1G
SCHEMBL31165337 0.69 KDM1A (0.45) KDM1AMAOBCACNB4CACNA1ACACNA1G
SCHEMBL21207007 0.68 BTK (0.51) KDM1AMAOBKMT2AGAA
SCHEMBL2209096 0.67 KDM1A (0.47) KDM1AMAOBKDM4DLIPGMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981886-B2 Antibiotics derivatives ACTELION PHARMACEUTICAL LTD. (CH) 2011-07-19 US disclosed
EP-1888574-B1 NEW ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 EP disclosed
US-20080280888-A1 Antibiotics Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2008-11-13 US disclosed
EP-1888574-A2 NEW ANTIBIOTIC DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2008-02-20 EP disclosed
WO-2006126171-A2 NEW ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280888-A1 Antibiotics Derivatives NR4A1, NR2C2, NR4A3 DYRK1A 3362/4885KDM1A 1522/4885MAOB 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.